Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,187.67 -0.03 (-0.00%) Dow
39,056.39 +172.13 (+0.44%) Nasdaq
16,302.76 -29.80 (-0.18%) Bitcoin USD
61,191.20 -1,141.44 (-1.83%) CMC Crypto 200
1,300.57 +5.90 (+0.46%)
Biodesix, Inc. (BDSX)
After hours:
| Previous close | 1.5500 |
| Open | 1.5000 |
| Bid | 1.5500 x 100 |
| Ask | 0.0000 x 0 |
| Day's range | 1.5000 - 1.5700 |
| 52-week range | 1.0300 - 2.2100 |
| Volume | |
| Avg. volume | 144,108 |
| Market cap | 177.763M |
| Beta (5Y monthly) | 1.12 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management
LOUISVILLE, Colo., May 08, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update.
- Business Wire
Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference
LOUISVILLE, Colo., May 07, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the 2024 RBCCM Global Healthcare Conference, which will be held from May 14-15, 2024.
- Business Wire
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
LOUISVILLE, Colo., April 24, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
